Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.
Monique K Van der KooijEls M E VerdegaalMarten VisserLinda de BruinCaroline E van der MinnePauline M MeijInge C F M RoozenMare A JonkerShelley van den BoschGerrit-Jan LiefersFrank M SpeetjensSjoerd H van der BurgEllen KapiteijnPublished in: BMJ open (2020)
NCT03638375; Pre-results.